Published on 22/12/2025
Research Ethics Committees and Their Role in UK Clinical Trials
Research Ethics Committees (RECs) are a fundamental component of the UK’s clinical research governance system, ensuring that the rights, safety, dignity, and well-being of participants are prioritised. Operating under the Health Research Authority (HRA), RECs review clinical trial protocols, consent documents, and supporting materials to confirm that trials are ethically designed and conducted. In parallel, the Medicines and Healthcare products Regulatory Agency (MHRA) provides regulatory oversight to confirm compliance with Good Clinical Practice (GCP) and applicable legislation. This dual system reinforces the ethical and scientific integrity of trials carried out within the UK’s NHS and academic infrastructure.
The following sections detail the functions of UK RECs, the regulatory frameworks they operate within, and their impact on clinical trial approvals and conduct.
Background and Regulatory Framework
HRA Oversight of RECs
The HRA oversees RECs across the UK, ensuring they function under a harmonised governance framework. Ethics submissions are made through the Integrated Research Application System (IRAS), which streamlines approval processes for multi-site and multi-country trials.
Medicines for Human Use (Clinical Trials) Regulations 2004
These regulations require REC approval for all interventional trials involving investigational medicinal products. RECs
International Alignment
REC reviews in the UK align with ICH E6(R2) GCP standards, ensuring trial data is ethically and scientifically credible for use in global submissions to EMA, FDA, and other agencies.
Core Insights: REC Role in UK Trials
1. Ethical Review of Protocols
RECs assess whether study designs minimise risks, maximise benefits, and align with patient protection principles. They examine inclusion/exclusion criteria, recruitment methods, and risk mitigation strategies.
2. Informed Consent Oversight
Consent forms and patient information sheets are scrutinised to ensure clarity, accessibility, and compliance with GDPR. RECs require lay summaries that patients and families can easily understand.
3. Participant Safety Monitoring
RECs evaluate safety monitoring strategies, including adverse event reporting and independent oversight by Data Monitoring Committees (DMCs).
4. Multi-Site and Multi-National Trials
UK RECs provide opinions that are valid across multiple NHS Trusts, reducing duplication and accelerating trial initiation. For multinational studies, REC approval complements MHRA authorisation.
5. REC Membership and Expertise
Committees comprise healthcare professionals, scientists, and lay members, ensuring a balanced review that considers scientific, ethical, and community perspectives.
Best Practices for Engaging with UK RECs
- Prepare comprehensive and patient-friendly informed consent materials.
- Submit complete applications through IRAS, including clear trial protocols and safety plans.
- Engage early with RECs for complex or high-risk studies such as ATMPs or FIH trials.
- Maintain open communication with RECs regarding substantial amendments.
- Ensure transparency in data protection, confidentiality, and participant rights management.
Scientific and Regulatory Evidence
- Medicines for Human Use (Clinical Trials) Regulations 2004
- ICH E6(R2) – Good Clinical Practice
- HRA Governance Framework for Health and Social Care Research
- GDPR and Data Protection Act 2018
- MHRA GCP Inspection Reports
Special Considerations
- Oncology Trials: RECs focus on clear disclosure of risks associated with complex therapies and novel combinations.
- Rare Diseases: Ethical concerns around small patient pools and potential therapeutic misconception require extra safeguards.
- Pediatrics: Parental consent and child assent are carefully scrutinised for compliance with ethical norms.
- ATMPs: Gene and cell therapy studies undergo enhanced REC review due to long-term safety considerations.
When Sponsors Should Seek REC Advice
- For first-in-human or high-risk studies with novel mechanisms of action.
- If patient groups are vulnerable, such as paediatrics, elderly, or rare disease populations.
- When developing consent processes for digital trials or eConsent models.
- For multinational trials requiring harmonisation of ethical standards.
- When addressing GDPR implications for sensitive patient data.
FAQs
1. What is the role of RECs in UK clinical trials?
RECs review trial protocols, consent forms, and supporting documents to ensure trials are ethically sound and participant rights are protected.
2. Do all UK trials require REC approval?
Yes. All interventional trials involving investigational products must secure REC approval in addition to MHRA authorisation.
3. How do sponsors apply to RECs?
Applications are submitted through the Integrated Research Application System (IRAS), which streamlines ethics and governance approvals.
4. Who sits on a REC?
Committees include healthcare professionals, scientists, and lay members, ensuring a balanced perspective in reviews.
5. Are REC opinions legally binding?
Yes. A favourable REC opinion is required before a trial can legally commence in the UK.
6. Can REC opinions cover multiple sites?
Yes. REC approval is valid across all NHS sites involved in a trial, avoiding the need for duplicate reviews.
7. What are common REC concerns?
Issues often include inadequate consent documentation, insufficient safety monitoring, or lack of clarity in participant materials.
Conclusion
Research Ethics Committees are a cornerstone of UK clinical trial governance, ensuring ethical conduct, participant protection, and scientific credibility. Working under HRA oversight and aligned with MHRA regulatory frameworks, RECs review trial protocols, consent procedures, and safety monitoring to ensure compliance with both ethical and scientific standards. Sponsors and investigators engaging with RECs should prioritise transparency, participant-focused communication, and robust safety planning to maintain public trust and regulatory acceptance of UK trial data.